Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CYTX
- CUSIP: 23283K10
- Web: www.cytori.com
Capitalization:- Market Cap: $11.2 million
- Outstanding Shares: 32,478,000
Average Prices:- 50 Day Moving Avg: $0.69
- 200 Day Moving Avg: $1.16
- 52 Week Range: $0.31 - $2.29
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.75
- P/E Growth: 0.0000
Sales & Book Value:- Annual Revenue: $8.75 million
- Price / Sales: 1.20
- Book Value: $0.34 per share
- Price / Book: 0.96
Profitability:- EBIDTA: ($17,750,000.00)
- Net Margins: -450.34%
- Return on Equity: -202.62%
- Return on Assets: -65.54%
Debt:- Debt-to-Equity Ratio: 0.69%
- Current Ratio: 1.18%
- Quick Ratio: 0.62%
Misc:- Average Volume: 796,781 shs.
- Beta: 2.93
- Short Ratio: 2.34
Frequently Asked Questions for Cytori Therapeutics (NASDAQ:CYTX)
What is Cytori Therapeutics' stock symbol?
Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."
When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?
Cytori Therapeutics's stock reverse split on the morning of Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.
How were Cytori Therapeutics' earnings last quarter?
Cytori Therapeutics Inc (NASDAQ:CYTX) issued its earnings results on Thursday, August, 10th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02. The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.23 million. Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. Cytori Therapeutics's revenue was down 18.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.43) EPS. View Cytori Therapeutics' Earnings History.
When will Cytori Therapeutics make its next earnings announcement?
Where is Cytori Therapeutics' stock going? Where will Cytori Therapeutics' stock price be in 2017?
2 equities research analysts have issued 1 year target prices for Cytori Therapeutics' shares. Their forecasts range from $2.30 to $5.00. On average, they anticipate Cytori Therapeutics' stock price to reach $3.65 in the next twelve months. View Analyst Ratings for Cytori Therapeutics.
What are analysts saying about Cytori Therapeutics stock?
Here are some recent quotes from research analysts about Cytori Therapeutics stock:
- 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (7/12/2017)
- 2. Maxim Group analysts commented, "With the closure of the Azaya acquisition announced this morning, we now assume a 15% market share and 35% royalty rate for the $300M European Liposomal Doxorubicin market with the first year of commercial sales in 2019. We recognize that a US fast track strategy could put Cytori's Doxorubicin in the US market (even before Europe) but for conservatism we do not assume US revenues in our model (nor do we assume Japan, or any other geographies which will likely evolve as well). We believe our 15% share and 35% royalty rates are both realistic (and market share could be conservative). The result of these changes is our valuation target now changes from $6 to $10 per share." (2/15/2017)
Who are some of Cytori Therapeutics' key competitors?
Who are Cytori Therapeutics' key executives?
Cytori Therapeutics' management team includes the folowing people:
- David M. Rickey, Independent Chairman of the Board
- Marc H. Hedrick M.D., President, Chief Executive Officer, Director
- Tiago Girao, Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
- Seijiro N. Shirahama, President , Asia Pacific
- John David Harris, Vice President, General Manager - Cell Therapy
- Jeremy Bragg Hayden, Vice President - Business Development, General Counsel
- Mark Marino M.D., Chief Medical Officer
- Gregg A. Lapointe, Director
- Richard James Hawkins, Independent Director
- Gary A. Lyons, Independent Director
Who owns Cytori Therapeutics stock?
Cytori Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perkins Capital Management Inc. (2.69%) and Vanguard Group Inc. (1.89%). Company insiders that own Cytori Therapeutics stock include David Rickey, Gail K Naughton, Jeremy B Hayden, John David Harris, Marc H Hedrick, Steven Kesten and Tommy G Thompson. View Institutional Ownership Trends for Cytori Therapeutics.
Who bought Cytori Therapeutics stock? Who is buying Cytori Therapeutics stock?
Cytori Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Vanguard Group Inc.. Company insiders that have bought Cytori Therapeutics stock in the last two years include David Rickey, Gail K Naughton, Jeremy B Hayden, John David Harris, Marc H Hedrick, Steven Kesten and Tommy G Thompson. View Insider Buying and Selling for Cytori Therapeutics.
How do I buy Cytori Therapeutics stock?
Shares of Cytori Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytori Therapeutics' stock price today?
One share of Cytori Therapeutics stock can currently be purchased for approximately $0.32.
MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cytori Therapeutics (NASDAQ:CYTX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $3.65 (1,031.78% upside) |
Analysts' Ratings History for Cytori Therapeutics (NASDAQ:CYTX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/16/2017 | B. Riley | Reiterated Rating | Neutral | | Medium |  |
| 8/11/2017 | Maxim Group | Set Price Target | Buy -> Buy | $10.00 -> $5.00 | High | |
| 6/28/2016 | Roth Capital | Reiterated Rating | Buy | $11.00 | N/A | |
(Data available from 8/19/2015 forward)
Earnings History for Cytori Therapeutics (NASDAQ:CYTX)Earnings History by Quarter for Cytori Therapeutics (NASDAQ CYTX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | | | | | | | |
| 8/10/2017 | Q2 2017 | ($0.16) | ($0.18) | $2.23 million | $0.90 million | View | N/A | |
| 5/11/2017 | Q1 2017 | ($0.31) | ($0.26) | $2.32 million | $0.60 million | View | N/A | |
| 3/23/2017 | Q4 16 | ($0.23) | ($0.24) | $3.36 million | $1.50 million | View | N/A | |
| 11/9/2016 | Q316 | ($0.24) | ($0.26) | $2.85 million | $2.61 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.39) | ($0.43) | $2.50 million | $1.10 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.03) | ($0.41) | $2.05 million | $2.90 million | View | Listen | |
| 3/3/2016 | Q4 | ($0.04) | ($0.03) | $2.90 million | $1.56 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.06) | ($0.04) | $5.27 million | $2.48 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.03) | ($0.03) | $2.50 million | $1.60 million | View | N/A | |
| 5/11/2015 | Q115 | ($0.07) | ($0.07) | $2.44 million | $0.90 million | View | Listen | |
| 3/12/2015 | Q4 14 | ($0.08) | ($0.08) | $3.10 million | $2.47 million | View | N/A | |
| 11/6/2014 | Q3 2014 | ($0.09) | ($0.12) | $4.31 million | $1.10 million | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.11) | ($0.15) | $2.76 million | $0.94 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.14) | ($0.14) | $2.87 million | $1.03 million | View | N/A | |
| 3/12/2014 | Q413 | ($0.12) | ($0.14) | $4.37 million | $2.71 million | View | N/A | |
| 11/7/2013 | Q313 | ($0.11) | ($0.08) | $3.17 million | $8.70 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.13) | ($0.16) | $2.88 million | $6.00 million | View | N/A | |
| 5/9/2013 | Q1 2013 | ($0.16) | ($0.11) | | | View | N/A | |
| 11/8/2012 | Q312 | ($0.15) | ($0.19) | $2.25 million | $1.31 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cytori Therapeutics (NASDAQ:CYTX)2017 EPS Consensus Estimate: ($0.77)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
| Q2 2017 | 1 | ($0.25) | ($0.25) | ($0.25) |
| Q3 2017 | 1 | ($0.12) | ($0.12) | ($0.12) |
| Q4 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
(Data provided by Zacks Investment Research)
Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cytori Therapeutics (NASDAQ:CYTX)Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 10.01%
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/10/2016 | John David Harris | VP | Buy | 2,500 | $2.03 | $5,075.00 | |
| 6/14/2016 | Gail K Naughton | Director | Buy | 1,000 | $2.10 | $2,100.00 | |
| 5/13/2016 | John David Harris | VP | Buy | 2,000 | $2.71 | $5,420.00 | |
| 3/9/2016 | David Rickey | Director | Buy | 150,000 | $0.19 | $28,500.00 | |
| 9/3/2015 | Tommy G Thompson | Director | Buy | 25,449 | $0.37 | $9,416.13 | |
| 9/2/2015 | Jeremy B Hayden | VP | Buy | 8,200 | $0.36 | $2,952.00 | |
| 8/28/2015 | David Rickey | Director | Buy | 56,000 | $0.31 | $17,360.00 | |
| 8/28/2015 | Marc H Hedrick | CEO | Buy | 11,200 | $0.31 | $3,472.00 | |
| 8/27/2015 | David Rickey | Director | Buy | 75,000 | $0.31 | $23,250.00 | |
| 8/21/2015 | David Rickey | Director | Buy | 50,000 | $0.38 | $19,000.00 | |
| 8/21/2015 | Marc H Hedrick | CEO | Buy | 5,000 | $0.38 | $1,900.00 | |
| 8/20/2015 | Marc H Hedrick | CEO | Buy | 10,000 | $0.40 | $4,000.00 | |
| 8/19/2015 | David Rickey | Director | Buy | 48,600 | $0.39 | $18,954.00 | |
| 8/19/2015 | Steven Kesten | VP | Buy | 6,000 | $0.39 | $2,340.00 | |
| 8/18/2015 | David Rickey | Director | Buy | 51,400 | $0.39 | $20,046.00 | |
| 8/18/2015 | Marc H Hedrick | CEO | Buy | 10,000 | $0.39 | $3,900.00 | |
| 8/18/2015 | Tiago Girao | CFO | Buy | 25,000 | $0.39 | $9,750.00 | |
| 11/13/2014 | David Rickey | Director | Buy | 20,000 | $0.47 | $9,400.00 | |
| 11/12/2014 | David Rickey | Director | Buy | 200,000 | $0.39 | $78,000.00 | |
| 11/12/2014 | Tiago Girao | CFO | Buy | 60,000 | $0.39 | $23,400.00 | |
| 11/11/2014 | Tiago Girao | CFO | Buy | 15,889 | $0.39 | $6,196.71 | |
| 6/5/2014 | David Rickey | Director | Buy | 30,000 | $2.34 | $70,200.00 | |
| 9/12/2013 | David Rickey | Director | Buy | 7,100 | $2.55 | $18,105.00 | |
| 9/11/2013 | David Rickey | Director | Buy | 2,000 | $2.58 | $5,160.00 | |
| 9/9/2013 | David Rickey | Director | Buy | 5,000 | $2.31 | $11,550.00 | |
| 9/5/2013 | David Rickey | Director | Buy | 2,000 | $2.24 | $4,480.00 | |
| 9/3/2013 | David Rickey | Director | Buy | 7,000 | $2.14 | $14,980.00 | |
| 8/30/2013 | Tommy G Thompson | Director | Buy | 5,000 | $2.14 | $10,700.00 | |
| 12/19/2012 | Lloyd H Dean | Director | Buy | 25,000 | $2.85 | $71,250.00 | |
| 12/19/2012 | Marc H Hedrick | President | Buy | 10,000 | $2.85 | $28,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cytori Therapeutics (NASDAQ:CYTX)
Latest Headlines for Cytori Therapeutics (NASDAQ:CYTX)
| Source: |
|
| Date | Headline |
|---|
 | Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment
finance.yahoo.com - August 17 at 7:00 PM |
 | Cytori Therapeutics' (CYTX) Neutral Rating Reaffirmed at B. Riley
www.americanbankingnews.com - August 16 at 10:56 PM |
 | Health Care Sector Update for 08/16/2017: CYTX,IDXG,JAGX - Nasdaq
www.nasdaq.com - August 16 at 6:10 PM |
| Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
finance.yahoo.com - August 16 at 6:10 PM |
| Cytori Therapeutics Inc (NASDAQ:CYTX) Given a $5.00 Price Target at Maxim Group
www.americanbankingnews.com - August 13 at 3:32 PM |
| Edited Transcript of CYTX earnings conference call or presentation 10-Aug-17 9:30pm GMT
finance.yahoo.com - August 12 at 10:11 PM |
 | Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 12 at 4:17 AM |
| Cytori Therapeutics' (NASDAQ:CYTX) "Neutral" Rating Reaffirmed at B. Riley
www.americanbankingnews.com - August 11 at 4:04 PM |
 | EARNINGS SUMMARY: Details of Cytori Therapeutics Inc. Q2 Earnings Report
www.rttnews.com - August 11 at 12:03 AM |
| Cytori Therapeutics Inc (NASDAQ:CYTX) Issues Earnings Results
www.americanbankingnews.com - August 10 at 10:42 PM |
| Cytori Reports Second Quarter 2017 Business and Financial Results
finance.yahoo.com - August 10 at 7:01 PM |
| Investor Network: Cytori Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - August 10 at 7:01 PM |
| Cytori reports 2Q loss
finance.yahoo.com - August 10 at 7:01 PM |
| Cytori Therapeutics Inc (CYTX) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - August 7 at 10:48 AM |
| Cytori to Webcast Second Quarter Financial Results on August 10
finance.yahoo.com - August 4 at 6:01 PM |
 | Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case - TheStreet.com
www.thestreet.com - July 31 at 5:36 PM |
| Cytori Therapeutics' (CYTX) "Neutral" Rating Reaffirmed at B. Riley
www.americanbankingnews.com - July 30 at 7:14 AM |
 | B. Riley Downgrades Cytori Therapeutics, Inc. (CYTX) to Neutral - StreetInsider.com
www.streetinsider.com - July 27 at 11:13 PM |
| Today's Research Reports on Stocks to Watch: Cytori Therapeutics and Novavax
finance.yahoo.com - July 26 at 3:51 AM |
 | 20 Biggest Mid-Day Losers For Tuesday | Benzinga - Benzinga
www.benzinga.com - July 25 at 10:47 PM |
| Cytori Therapeutics (CYTX) STAR Trial of Habeo Cell Therapy in Patients with Scleroderma Doesn't Met Primary Endpoint
www.streetinsider.com - July 24 at 10:28 PM |
| Analysts Remain Buyers of 2 Volatile Healthcare Stocks: Cytori Therapeutics Inc (CYTX) and TearLab Corp (TEAR)
finance.yahoo.com - July 24 at 5:26 PM |
| Cytori Says STAR Trial Fails To Meet Primary Or Secondary Efficacy Endpoints
www.nasdaq.com - July 24 at 10:47 AM |
| Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Patients with Scleroderma
finance.yahoo.com - July 24 at 10:47 AM |
| Zacks Investment Research Lowers Cytori Therapeutics Inc (CYTX) to Hold
www.americanbankingnews.com - July 12 at 7:10 PM |
| Cytori Therapeutics Inc (NASDAQ:CYTX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:04 PM |
| Cytori Therapeutics (CYTX) Says AMA Approves New Category III ... - StreetInsider.com
www.streetinsider.com - July 10 at 5:39 PM |
| American Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma Therapy
finance.yahoo.com - July 10 at 5:39 PM |
| Are Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock? - Nasdaq
www.nasdaq.com - July 8 at 10:07 AM |
| Cytori Therapeutics (CYTX) Issued Key Patents for Scleroderma - StreetInsider.com
www.streetinsider.com - July 8 at 10:07 AM |
| Are Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock?
finance.yahoo.com - July 8 at 10:07 AM |
| Pre-Open Movers 07/06: (HSNI) (BGNE) (CYTX) Higher; (EGLT) (TAHO) (AZZ) Lower (more...)
www.streetinsider.com - July 6 at 3:16 PM |
| ETFs with exposure to Cytori Therapeutics, Inc. : July 5, 2017
finance.yahoo.com - July 5 at 6:27 PM |
| Cytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin America
finance.yahoo.com - June 14 at 5:36 PM |
| Cytori Therapeutics (CYTX) Publishes Long-Term Safety Data on ... - StreetInsider.com
www.streetinsider.com - June 8 at 10:41 PM |
| Cytori Publishes Long Term Safety Data On Technology For Breast Reconstruction
www.rttnews.com - June 8 at 10:06 AM |
| Long Term Safety Data Published on Cytori Technology for Breast Reconstruction After Oncologic Surgery & Radiation Therapy
finance.yahoo.com - June 8 at 10:06 AM |
| ETFs with exposure to Cytori Therapeutics, Inc. : June 6, 2017
finance.yahoo.com - June 6 at 4:56 PM |
| ValuEngine Lowers Cytori Therapeutics Inc (CYTX) to Strong Sell
www.americanbankingnews.com - June 4 at 9:16 PM |
| Cytori Therapeutics Inc (CYTX) PT Set at $10.00 by Maxim Group
www.americanbankingnews.com - June 1 at 11:02 PM |
 | Cytori to Introduce Next-Generation Celution® Technology - GlobeNewswire (press release)
globenewswire.com - June 1 at 10:17 PM |
| Cytori to Introduce Next-Generation Celution® Technology
finance.yahoo.com - June 1 at 5:16 PM |
| Cytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Trial
finance.yahoo.com - May 31 at 9:58 AM |
| Cytori Therapeutics Inc (CYTX) Short Interest Update
www.americanbankingnews.com - May 28 at 7:16 AM |
| ETFs with exposure to Cytori Therapeutics, Inc. : May 25, 2017
finance.yahoo.com - May 25 at 6:25 PM |
| Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 12:38 PM |
| Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
finance.yahoo.com - May 23 at 12:32 PM |
| Cytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor Conference
finance.yahoo.com - May 16 at 12:06 PM |
| FY2019 EPS Estimates for Cytori Therapeutics Inc Lowered by B. Riley (CYTX)
www.americanbankingnews.com - May 15 at 10:10 AM |
| B. Riley Reaffirms "Buy" Rating for Cytori Therapeutics Inc (CYTX)
www.americanbankingnews.com - May 14 at 10:14 PM |
Cytori Therapeutics (CYTX) Chart for Saturday, August, 19, 2017
